A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Capacity 2
  • Sponsors InterMune
  • Most Recent Events

    • 24 May 2017 Results (n=1247) of pooled analysis comparing the effect of pirfenidone on progression-free survival (PFS) using a pre-specified PFS definition versus a novel definition of PFS using data from phase III trials (ASCEND or CAPACITY), presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results of a subgroup analysis in patients stratified by GAP stage and FVC value from three randomised trials (ASCEND and CAPACITY trials; n=1247), presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of pooled subgroup analysis from ASCEND and CAPACITY trials presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top